SCHEMBL18096035

SCHEMBL18096035

COc1ccc(Cn2ccc(N3CCN(C(=O)OC(C)(C)C)C(C)(C)C3=O)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.43
▸ CACNA1H O95180 5/20 0.41
▸ CACNA1G O43497 3/20 0.41
▸ CACNA1I Q9P0X4 3/20 0.41
▸ BACE1 P56817 2/20 0.40
▸ CTSD P07339 1/20 0.40
▸ CTSE P14091 1/20 0.40
▸ MAPT P10636 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ AADAT Q8N5Z0 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ P2RX3 P56373 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ HDAC1 Q13547 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ HDAC5 Q9UQL6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19895449 0.88 KDM1A (0.36) KDM1ACACNA1HCACNA1GCACNA1IBACE1
SCHEMBL18096320 0.84 BACE1 (0.40) KDM1ABACE1CTSDCTSEMAPT
SCHEMBL19913894 0.83 KDM1A (0.43) KDM1ACACNA1HBACE1CTSDCTSE
SCHEMBL18096166 0.81 BACE1 (0.38) KDM1ABACE1CTSDCTSEMAPT
SCHEMBL18096189 0.80 BACE1 (0.40) KDM1ACACNA1HBACE1CTSDCTSE
SCHEMBL18096366 0.79 TP53 (0.40) KDM1ACACNA1HBACE1CTSDCTSE
SCHEMBL18096182 0.78 CACNA1G (0.42) CACNA1HCACNA1GCACNA1IMAPTAADAT
SCHEMBL18096370 0.73 CACNA1G (0.34) KDM1ACACNA1HCACNA1GCACNA1IAADAT
SCHEMBL18096081 0.72 SCD (0.44) MAPTLMNATP53
SCHEMBL22660425 0.72 CACNA1H (0.43) KDM1ACACNA1HCACNA1GCACNA1IBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180057505-A1 BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY VERTEX PHARMACEUTICALS INCORPORATED 2018-03-01 — — US disclosed
WO-2016154075-A1 BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180057505-A1 BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY F2RL1, PARP12, TFPI2 KDM1A 4316/4885CACNA1H 4745/4885CACNA1G 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback